tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

BOLT Stock Latest News

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Press ReleasesBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
1M ago
BOLT
Bolt Biotherapeutics reports Q4 EPS (47c), consensus (48c)
PremiumThe Fly
Bolt Biotherapeutics reports Q4 EPS (47c), consensus (48c)
1M ago
BOLT
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
PremiumPress Releases
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
2M ago
BOLT
Bolt Biotherapeutics enrolls first patient in Phase 2 study of BDC-1001
PremiumThe Fly
Bolt Biotherapeutics enrolls first patient in Phase 2 study of BDC-1001
5M ago
BOLT
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
PremiumPress Releases
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
5M ago
BOLT
Bolt Biotherapeutics sees cash funding operations, milestones through 2025
PremiumThe FlyBolt Biotherapeutics sees cash funding operations, milestones through 2025
6M ago
BOLT
Bolt Biotherapeutics reports Q3 EPS (43c), consensus (49c)
PremiumThe Fly
Bolt Biotherapeutics reports Q3 EPS (43c), consensus (49c)
6M ago
BOLT
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
PremiumPress Releases
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
6M ago
BOLT
Bolt presents updated clinical data from Phase 1 trial of BDC-1002
PremiumThe Fly
Bolt presents updated clinical data from Phase 1 trial of BDC-1002
6M ago
BOLT
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
PremiumPress Releases
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
6M ago
BOLT
Bolt Biotherapeutics reports first patient dosed in Phase 1/2 study of BDC-3042
PremiumThe Fly
Bolt Biotherapeutics reports first patient dosed in Phase 1/2 study of BDC-3042
6M ago
BOLT
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
PremiumPress Releases
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
6M ago
BOLT
Bolt Biotherapeutics to present clinical data from Phase 1/2 study of BDC-1001
PremiumThe FlyBolt Biotherapeutics to present clinical data from Phase 1/2 study of BDC-1001
6M ago
BOLT
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
PremiumPress Releases
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
6M ago
BOLT
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
PremiumPress Releases
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
7M ago
BOLT
Bolt Biotherapeutics announces U.S. FDA granted ODD for BDC-1001
PremiumThe Fly
Bolt Biotherapeutics announces U.S. FDA granted ODD for BDC-1001
7M ago
BOLT
Bolt Biotherapeutics treatment of gastric cancer granted orphan designation
PremiumThe Fly
Bolt Biotherapeutics treatment of gastric cancer granted orphan designation
7M ago
BOLT
Bolt Biotherapeutics announces issuance of U.S. patent covering BDC-3042
PremiumThe Fly
Bolt Biotherapeutics announces issuance of U.S. patent covering BDC-3042
8M ago
BOLT
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
PremiumPress Releases
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
8M ago
BOLT
Bolt Biotherapeutics to Participate in September Investor Conferences
PremiumPress ReleasesBolt Biotherapeutics to Participate in September Investor Conferences
8M ago
BOLT
Bolt Biotherapeutics price target lowered to $6 from $7 at Stifel
PremiumThe Fly
Bolt Biotherapeutics price target lowered to $6 from $7 at Stifel
9M ago
BOLT
Bolt Biotherapeutics reports Q2 EPS (48c), consensus (49c)
PremiumThe Fly
Bolt Biotherapeutics reports Q2 EPS (48c), consensus (49c)
9M ago
BOLT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >